Levin Capital Strategies L.P. Trims Holdings in Novelion Therapeutics Inc (NVLN)

Levin Capital Strategies L.P. trimmed its stake in Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT) by 67.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 50,695 shares of the biotechnology company’s stock after selling 107,181 shares during the period. Levin Capital Strategies L.P.’s holdings in Novelion Therapeutics were worth $158,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. TIAA CREF Investment Management LLC acquired a new stake in Novelion Therapeutics in the second quarter worth $377,000. Northern Trust Corp acquired a new stake in Novelion Therapeutics in the second quarter worth $1,251,000. Healthcare Value Capital LLC grew its holdings in Novelion Therapeutics by 13.5% in the fourth quarter. Healthcare Value Capital LLC now owns 1,000,000 shares of the biotechnology company’s stock worth $3,120,000 after purchasing an additional 118,560 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Novelion Therapeutics by 424.3% in the third quarter. Schwab Charles Investment Management Inc. now owns 135,783 shares of the biotechnology company’s stock worth $955,000 after purchasing an additional 109,883 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Novelion Therapeutics in the second quarter worth $380,000. Institutional investors and hedge funds own 85.03% of the company’s stock.

NVLN has been the subject of a number of research reports. Zacks Investment Research cut shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. Royal Bank of Canada dropped their price objective on shares of Novelion Therapeutics from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. Finally, ValuEngine raised shares of Novelion Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, February 3rd.

Novelion Therapeutics Inc (NVLN) opened at $4.27 on Monday. Novelion Therapeutics Inc has a 12 month low of $3.08 and a 12 month high of $12.12. The company has a current ratio of 1.45, a quick ratio of 1.28 and a debt-to-equity ratio of 6.53.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2018/02/19/levin-capital-strategies-l-p-trims-holdings-in-novelion-therapeutics-inc-nvln.html.

Novelion Therapeutics Profile

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Want to see what other hedge funds are holding NVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novelion Therapeutics Inc (NASDAQ:NVLN) (TSE:QLT).

Institutional Ownership by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply